Generated: 2026-10-15T19:00:47Z
> build_esen_ranks failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011Cg4YCTw2FghaoMQEwb3n6'}
JNJ Analyst Price Target Forecast - ESEN Analytics
JNJ analyst price target: $279.19 average (range $255.0-$305.0), based on 17 Wall Street analysts.
ESEN AI Commentary: Analysts have raised targets following JNJ's execution on new drug launches and resolution of talc litigation uncertainty; the disagreement centers on whether near-term gains in Innovative Medicine and MedTech can sustain double-digit growth into 2030 without M&A, with optimists citing established pipeline momentum offsetting STELARA biosimilar losses while skeptics worry tariff headwinds and drug pricing pressures could constrain 2026 guidance raises.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
Generated: 2026-10-11T23:49:37Z
> build_news_intel failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011CfwLzJLvBpPVRu4dh3L9i'}
Generated: 2026-09-29T23:55:39Z
> build_fundamental_earnings failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011CfYdk14MDeJoxShB8LuzG'}
JNJ Systematic Research
Systematic screening reveals Johnson & Johnson's defensive quality profile through a beta of 0.23, positioning the company as one of the lowest-volatility assets in the pharmaceutical sector. The valuation multiples reflect premium pricing, with a P/E of 29.53 and P/S of 6.34, while the company demonstrates institutional-grade profitability metrics including ROE of 25.74% and net margins of 21.48%. This combination suggests the market prices in sustained competitive advantages and predictable cash generation.
The fundamental model highlights several structural strengths:
- Profitability consistency: ROA of 10.6% and operating margins of 25.73% indicate efficient capital deployment across diversified healthcare segments
- Balance sheet discipline: D/E ratio of 0.59 provides financial flexibility while maintaining moderate leverage
- Revenue expansion: YoY revenue growth of 8.06% demonstrates resilience in a mature industry environment
The screener flags two notable concerns. EPS declined 7.75% year-over-year despite revenue growth, pointing to margin compression or non-operating headwinds requiring deeper examination. Additionally, the current ratio of 1.03 sits near the threshold for adequate liquidity coverage, leaving limited buffer for working capital stress scenarios.
Research perspective relative to peers (LLY, MRK, PFE) shows JNJ trading at a 57% discount to its 52-week high of $274.90, while the P/B multiple of 6.13 indicates the market assigns substantial value to intangible assets and market positioning. The combination of low beta, consistent profitability, and moderate growth characterizes JNJ as a stability-oriented pharmaceutical allocation within systematic portfolios seeking defensive healthcare exposure.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.